Skip to main content
SpringerLink
Log in

Entzündliche Gefäßerkrankungen

  • Chapter
Retinale Gefäßerkrankungen

  • 1390 Accesses

Zusammenfassung

Henry Eales, ein englischer Augenarzt, beschrieb diese Erkrankung vor nahezu 130 Jahren. Eales erste Beschreibung galt wiederholten Netzhaut und Glaskörperblutungen, zusammen mit Nasenbluten, Kopfschmerzen, peripheren Durchblutungsstörungen, Verdauungsstörungen und chronischer Verstopfung bei jungen Männern. Er hielt dies für eine vasomotorische Erkrankung, wobei eine Verengung der intestinalen Blutgefäße zu einer kompensatorischen Erweiterung der den Kopf versorgenden Blutgefäße führe, und dort Blutungen auslöse. Die Erkrankung wurde Eales zu Ehren nach ihm benannt, obwohl Wadsworth (1887) nur fünf Jahre später als erster die damit verbundenen entzündlichen Prozesse beschrieb. Duke- Elder hielt Morbus Eales für den klinischen Ausdruck vielfältiger Erkrankungen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Literatur zu Abschnitt 14.1

  • Badrinath SS, Gopal L, Sharma T et al. (1999) Vitreoschisis in Eales’ disease; pathogenic role and significance in surgery. Retina. 19:51–54

    Article  PubMed  CAS  Google Scholar 

  • Bali T, Saxena S, Kumar D (2005) Response time and safety profile of pulsed oral methotrexate therapy in idiopathic retinal periphlebitis. Eur J Ophthalmol. 15(3):374–8.

    PubMed  CAS  Google Scholar 

  • Biswas J, Raghavendran R et al. (2001) Presumed Eales disease with neurologic involvement: report of three cases. Retina. 21(2):141–5.

    Article  PubMed  CAS  Google Scholar 

  • Biswas J, Mukesh BN, Narain S, Roy S, Madhavan HN (1998) Profiling of human leukocyte antigen in Eales’ disease. Int Ophthalmol 21:277–81.

    Article  CAS  Google Scholar 

  • Biswas J, Badrinath SS (1995–96) Ocular morbidity in patients with active systemic tÜberculosis. Int Ophthalmol. 19(5):293–298.

    Google Scholar 

  • Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S (2002) Eales disease- an update. Surv of Ophthalmol 47(13):197–214.

    Article  Google Scholar 

  • Chanana B, Azad RV, Patwardhan S (2010) Role of intravitreal bevacizumab in the management of Eales’ disease. Int Ophthalmol. 30:57–61.

    Article  PubMed  Google Scholar 

  • Charmis J (1965) On the classification and management of the evolutionary course of Eales’ disease. Trans Ophthalmol Soc UK,85:187

    Google Scholar 

  • Eales H (1882) Primary retinal haemorrhage in young men. Ophthalmic Rev. 1:41

    Google Scholar 

  • Eales H (1880) Retinal haemorrhages associated with epistaxis and constipation. Brim Med Rev. 9:262

    Google Scholar 

  • Elliot AJ (1975) Thirty years observation of patients with Eales’ disease. Am J Ophthalmol 80:404

    PubMed  CAS  Google Scholar 

  • Gadkari S (2007) Eales` Disease. In: Joussen AM, Gardner TW, Kirchhof B, Ryan SJ (Hrsg) Retinal Vascular Disease. Springer Berlin Heidelberg, p 613–627

    Chapter  Google Scholar 

  • Gadkari SS, Kamdar P, Jehangir RP (1992) Pars plana Vitrectomy in Vitreous haemorrhage due to Eales’ disease. Ind J Ophthalmol 40

    Google Scholar 

  • Gunisha P, Madhavan HN, Jayanthi U, Therese KL (2000) Polymerase chain reaction using IS6110 primer to detect Mycobacterium tÜberculosis in clinical samples. Indian J Path Microbiol 43:395–402.

    CAS  Google Scholar 

  • Madhavan, HN. Therese KL, Gunisha P, Jayanthi U, Biswas J (2000) Polymerase Chain Reaction for detection of Mycobacterium tÜberculosis in epiretinal membrane in Eales’ disease. Invest Ophthalmol Vis Sci 41:822–25.

    PubMed  CAS  Google Scholar 

  • Majji AB,Vemuganti GK, Shah VA et al. (2006) A comparative study of epiretinal membranes associated with Eales’ disease: a clinicopathologic evaluation. Eye 20:46–54

    Article  PubMed  CAS  Google Scholar 

  • Malik SRK, Patnaik B (1973) Fluorescein angiography in Eales’ disease. Ind J Ophthalmol. 21:5

    CAS  Google Scholar 

  • Murphy RP, Renie WA, Proctor LR, Shimuzu H, Lippmann SM, Anderson KC, Fine SL, Patz A, McKusick VA (1983) A survey of patients with Eales’ disease, in Fine SL and Owen SL(eds):Management of retinal vascular and macular disorders,Baltimore,Md, William and Wilkin

    Google Scholar 

  • Perentes Y, Chan CC, Bovey E, Uffer S, Herbort CP (2002) Massive vascular endothelium growth factor (VEGF) expression in Eales’ disease. Klin Monbl Augenheilkd. 219:311–4.

    Article  PubMed  Google Scholar 

  • Renie WA, Murphy RP, Anderson KC, et al. (1983) The evaluation of patients with Eales’ disease. Retina 3:243–248

    Article  PubMed  CAS  Google Scholar 

  • Saxena S, Kumar D (2004) A new staging system for idiopathic retinal periphlebitis. Eur J Ophthalmol. 14(3):236–9.

    PubMed  CAS  Google Scholar 

  • Shanmugam MP, Badrinath SS, Gopal L, Sharma T (1998) Long term visual results of vitrectomy for Eales’ disease complications.Int Ophthalmol. 22(1):61–4.

    Article  PubMed  CAS  Google Scholar 

  • Spitznas M, Meyer-Schwickerath GT, Stephen B (1975) Clinical Picture of Eales’ disease. Grafes Arch Clin Exp Ophthalmol 194:73

    Article  CAS  Google Scholar 

  • Theodosisadis G (1970) Fluorescein anigography in Eales’ disease. Am J Ophthalmol. 69:271

    Google Scholar 

  • Verma A, Biswas J, Radhakrishnan S, Narayanasamy A (2010) Intraocular expression of vascular endothelial growth factor (VEGF) and pigment epithelial-derived factor (PEDF) in a case of Eales’ disease by immunohistochemical analysis: a case report. Int Ophthalmol. 30:429–34.

    Article  PubMed  Google Scholar 

Literatur zu Abschnitt 14.2

  • Accinni L, Dixon FJ (1979). Degenerative vascular disease and myocardial infarction in mice with lupus-like syndrome. Am J Pathol 96(2): 477–492.

    PubMed  CAS  Google Scholar 

  • Arevalo JF, Lowder CY, et al. (2002). Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol 13(6): 404–410.

    Article  PubMed  Google Scholar 

  • Aronson AJ, Ordonez NG, et al. (1979). Immune-complex deposition in the eye in systemic lupus erythematosus. Arch Intern Med 139(11): 1312–1313.

    Article  PubMed  CAS  Google Scholar 

  • Asherson RA, Merry P, et al. (1989). Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the ‘primary’ antiphospholipid syndrome. Ann Rheum Dis 48(5): 358–361.

    Article  PubMed  CAS  Google Scholar 

  • Benucci M, Del Rosso A, et al. (2005). Systemic lupus erythematosus (SLE) in Italy: an Italian prevalence study based on a two-step strategy in an area of Florence (Scandicci-Le Signe). Med Sci Monit 11(9): CR420–425.

    Google Scholar 

  • Bertsias GK., Salmon JE, et al. (2010). Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Annals of Rheumatic Disease 69(9): 1603–1611.

    Article  Google Scholar 

  • Borchers AT, Naguwa SM, et al. (2010). The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9(5): A277–287.

    Article  PubMed  CAS  Google Scholar 

  • Boumpas DT, Austin HA 3rd, et al. (1995). Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 122(12): 940–950.

    PubMed  CAS  Google Scholar 

  • Boumpas DT, Fessler BJ, et al. (1995). Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 123(1): 42–53.

    PubMed  CAS  Google Scholar 

  • Cobo-Soriano R, Sanchez-Ramon S, et al. (1999). Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol 128(6): 725–732.

    Article  PubMed  CAS  Google Scholar 

  • Cordes FC, Aiken SD (1947). Ocular changes in acute disseminated lupus erythematosus; report of a case with microscopic changes. Am J Ophthalmol 30: 1541–1555.

    PubMed  CAS  Google Scholar 

  • Feinglass EJ, Arnett FC, et al. (1976). Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine 55(4): 323–339.

    Article  PubMed  CAS  Google Scholar 

  • Francis L, Perl A (2009). Pharmacotherapy of systemic lupus erythematosus. Expert Opin Pharmacother 10(9): 1481–1494.

    Article  PubMed  CAS  Google Scholar 

  • Galindo-Rodriguez G., Avina-Zubieta JA, et al. (1999). Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Am J Med 106(1): 65–69.

    Article  PubMed  CAS  Google Scholar 

  • Gold DH, Morris DA, et al. (1972). Ocular findings in systemic lupus erythematosus. Br J Ophthalmol 56(11): 800–804.

    Article  PubMed  CAS  Google Scholar 

  • Gourley MF, Austin HA 3rd, et al. (1996). „Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial.« Ann Intern Med 125(7): 549–557.

    CAS  Google Scholar 

  • Graham EM, Spalton DJ, et al. (1985). Cerebral and Retinal Vascular Changes in Systemic Lupus Erythematosus. Ophthalmology 92(3): 444–448.

    PubMed  CAS  Google Scholar 

  • Griffiths B, Mosca M, et al. (2005). Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19(5): 685–708.

    Article  PubMed  Google Scholar 

  • Hahn BH (1997). Systemic Lupus Erythematosus. In: Harrison TR et al. (Hrsg) Harrison’s Principles of Internal Medicine. McGraw Hill Text. 2: 1874–1880.

    Google Scholar 

  • Hochberg MC, Boyd RE, et al. (1985). Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore) 64(5): 285–295.

    CAS  Google Scholar 

  • Hochberg MC, Perlmutter DL, et al. (1995). Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. Lupus 4(6): 454–456.

    Article  PubMed  CAS  Google Scholar 

  • Jabs DA, Fine SL, et al. (1986). Severe retinal vaso-occlusive disease in systemic lupus erythematosus. Archives of Ophthalmology 104: 558–563.

    Article  PubMed  CAS  Google Scholar 

  • Jabs DA, Miller NR, et al. (1986). Optic neuropathy in systemic lupus erythematosus. Archives of Ophthalmology 104: 564–568.

    Article  PubMed  CAS  Google Scholar 

  • Jennette JC, Falk RJ, et al. (1994). Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37(2): 187–192.

    Article  PubMed  CAS  Google Scholar 

  • Karlson EW, Daltroy LH, et al. (1997). The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 40(1): 47–56.

    Article  PubMed  CAS  Google Scholar 

  • Karpik AG, Schwartz MM, et al. (1985). Ocular immune reactants in patients dying with systemic lupus erythematosus. Clin Immunol Immunopathol 35(3): 295–312.

    Article  PubMed  CAS  Google Scholar 

  • Lin YC, Wang AG, et al. (2009) Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. Acta Ophthalmol 87(2): 204–210.

    Article  PubMed  Google Scholar 

  • Lorenz HM, Grunke M, et al. (2005). Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus. Ann Rheum Dis 64(10): 1517–1519.

    Article  PubMed  Google Scholar 

  • Marmor MF (2003). New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum 48(6): 1764.

    Article  PubMed  Google Scholar 

  • Marmor MF, Carr RE, et al. (2002). Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 109(7): 1377–1382.

    Article  PubMed  Google Scholar 

  • Meister P (2003). Vasculitides: classification, clinical aspects and pathology. A review. Pathologe 24(3): 165–181.

    PubMed  Google Scholar 

  • Merrill JT, Neuwelt CM, et al. (2010). Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis and Rheumatism 62(1): 222–233.

    Article  PubMed  CAS  Google Scholar 

  • Montehermoso A, Cervera R, et al. (1999). Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Semin Arthritis Rheum 28(5): 326–332.

    Article  PubMed  CAS  Google Scholar 

  • Nag TC, Wadhwa S (2005). Histopathological changes in the eyes in systemic lupus erythematosus: an electron microscope and immunohistochemical study. Histol Histopathol 20(2): 373–382.

    PubMed  CAS  Google Scholar 

  • Petri M, Perez-Gutthann S, et al. (1991). Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 91(4): 345–353.

    Article  PubMed  CAS  Google Scholar 

  • Ramal LM, Lopez-Nevot MA, et al. (2004). Systemic lupus erythematosus in southern Spain: a comparative clinical and genetic study between Caucasian and Gypsy patients. Lupus 13(12): 934–940.

    Article  PubMed  CAS  Google Scholar 

  • Ramos-Casals M, Soto MJ, et al. (2009). Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 18(9): 767–776.

    Article  PubMed  CAS  Google Scholar 

  • Riemekasten G, Hahn BH (2005). Key autoantigens in SLE. Rheumatology 44(8): 975–982.

    Article  PubMed  CAS  Google Scholar 

  • Rosenbaum JT, Robertson JE Jr., et al. (1991). Retinal vasculitis–a primer. West J Med 154(2): 182–185.

    PubMed  CAS  Google Scholar 

  • Rosenbaum JT, Simpson J, et al. (1997). Successful treatment of optic neuritis in association with systemic lupus erythematosus using intravenous cyclophosphamide. British Journal of Ophthalmology 81: 130–132.

    Article  PubMed  CAS  Google Scholar 

  • Rosenbaum JT, Wernick R (1990). The utility of routine screening of patients with uveitis for systemic lupus erythematosus or tÜberculosis. A Bayesian analysis. Arch Ophthalmol 108(9): 1291–1293.

    Article  PubMed  CAS  Google Scholar 

  • Ruiz-Irastorza G, Khamashta MA, et al. (2001). Systemic lupus erythematosus. Lancet 357(9261): 1027–1032.

    Article  PubMed  CAS  Google Scholar 

  • Saleh Z, Menassa J, et al. (2010). Cranial nerve VI palsy as a rare initial presentation of systemic lupus erythematosus: case report and review of the literature. Lupus 19(2): 201–205.

    Article  PubMed  CAS  Google Scholar 

  • Soo MP, Chow SK, et al. (2000). »The spectrum of ocular involvement in patients with systemic lupus erythematosus without ocular symptoms.« Lupus 9(7): 511–514.

    Article  PubMed  CAS  Google Scholar 

  • Stafford-Brady FJ, Urowitz MB, et al. (1988). Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum 31(9): 1105–1110.

    Article  PubMed  CAS  Google Scholar 

  • Stahl-Hallengren C, Jonsen A, et al. (2000). Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 27(3): 685–691.

    PubMed  CAS  Google Scholar 

  • Tan EM, Cohen AS, et al. (1982). The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11): 1271–1277.

    Article  PubMed  CAS  Google Scholar 

  • Tuft SJ, Watson PG (1991). Progression of scleral disease. Ophthalmology 98(4): 467–471.

    PubMed  CAS  Google Scholar 

  • Wallace DJ, Stohl W, et al. (2009). A phase II, randomized, doubleblind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis and Rheumatism 61(9): 1168–1178.

    Article  PubMed  CAS  Google Scholar 

  • Wang TJ, Wang IJ, et al. (2010). Comorbidities of dry eye disease: a nationwide population-based study. Acta Ophthalmol.

    Google Scholar 

  • Wolfe F, Marmor MF (2010). Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62(6): 775–784.

    Article  CAS  Google Scholar 

Literatur zu Abschnitt 14.3

  • Deuter CME, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M (2008) Behçet’s disease: ocular effects and treatment. Prog Retin Eye Res 27:111–136.

    Article  PubMed  CAS  Google Scholar 

  • Deuter CME, Zierhut M, Mohle A, Vonthein R, Stubiger N, Kotter I (2010) Long-term remissions after cessation of interferon alpha treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum 62:2796–2805.

    Article  PubMed  CAS  Google Scholar 

  • Direskeneli H (2006) Autoimmunity vs autoinflammation in Behçet’s disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 45:1461–1465.

    Article  CAS  Google Scholar 

  • Gul A (2001) Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 19 (5 Suppl 24):S6–12.

    PubMed  CAS  Google Scholar 

  • Gul A, Inanc M, Ocal L, Aral O, Konice M (2000) Familial aggregation of BD in Turkey. Ann Rheum Dis 59:622–625.

    Article  PubMed  CAS  Google Scholar 

  • Gul A, Hajeer AH, Worthington J, Ollier WE, Silman AJ (2001) Linkage mapping of a novel susceptibility locus for Behçet’s disease to chromosome 6p22–23. Arthritis Rheum 44:2693–2696.

    Article  PubMed  CAS  Google Scholar 

  • Hamuryudan V, Özyazgan Y, Hizli N, Mat C, Yurdakul S, Tüzün Y, Şenocak M, Yazici H (1997) Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum 40:769–774.

    Article  PubMed  CAS  Google Scholar 

  • Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger N, Yurdakul S, Yazici H (2008) EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 67:1656–1662.

    Article  PubMed  CAS  Google Scholar 

  • International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080.

    Google Scholar 

  • Koné-Paut I, Sanchez E, Le Quellec A, Manna R, Touitou I (2007) Autoinflammatory gene mutations in Behçet’s disease. Ann Rheum Dis 66:832–834.

    Article  PubMed  CAS  Google Scholar 

  • Kötter I, Günaydin I, Batra M, Vonthein R, Stübiger N, Fierlbeck G, Melms A (2006) CNS involvement occurs more frequently in patients with Behçet’s disease under cyclosporin A (CSA) than under other medications – results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482–486.

    Article  PubMed  Google Scholar 

  • Kötter I, Günaydin I, Zierhut M, Stubiger N. The use of interferon α in Behçet disease: review of the literature. Semin Arthritis Rheum 2004;33:320–335.

    Article  PubMed  CAS  Google Scholar 

  • Mizuki N, Inoko H, Ando H, Nakamura S, Kashiwase K, Akaza T, Fujino Y, Masuda K, Takiguchi M, Ohno S (1993) Behçet’s disease associated with one of the HLA-B51 subantigens, HLA-B* 5101. Am J Ophthalmol 116:406–409.

    PubMed  CAS  Google Scholar 

  • Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, Le JM, Yang B, Korman BD, Cakiris A, Aglar O, Emrence Z, Azakli H, Ustek D, Tugal-Tutkun I, Akman-Demir G, Chen W, Amos CI, Dizon MB, Kose AA, Azizlerli G, Erer B, Brand OJ, Kaklamani VG, Kaklamanis P, Ben-Chetrit E, Stanford M, Fortune F, Ghabra M, Ollier WER, Cho YH, Bang D, O’Shea J, Wallace GR, Gadina M, Kastner DL, Gül A (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Gen 42:698–702.

    Article  CAS  Google Scholar 

  • Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358:295–296.

    Article  PubMed  CAS  Google Scholar 

  • Tugal-Tutkun I, Cingü K, Kir N, Yeniad B, Urgancioglu M, Gül A (2008) Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 246:1169–1177.

    Article  PubMed  Google Scholar 

  • Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gül A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease. Arthritis Rheum 52:2478–2484.

    Article  PubMed  CAS  Google Scholar 

  • Yasuoka H, Yamaguchi Y, Mizuki N, Nishida T, Kawakami Y, Kuwana M (2008) Preferential activation of circulating CD8+ and gammadelta T cells in patients with active Behçet’s disease and HLA-B51. Clin Exp Rheumatol 26 (4 Suppl 50):S59–63.

    PubMed  CAS  Google Scholar 

  • Zafirakis P, Foster CS (2002) Adamantiades-Behçet’s disease. In: Foster CS, Vitale AT, Saunders, Philadelphia, pp 632–652.

    Google Scholar 

  • Zierhut M, Mizuki N, Ohno S, Inoko H, Gül A, Onoé K, Isogai E (2003) Immunology and functional genomics of Behçet’s disease. Cell Mol Life Sci 60:1903–1922.

    Article  PubMed  CAS  Google Scholar 

  • Zouboulis CC (2003) Epidemiology of Adamantiades-Behçet’s disease. In: Zierhut M, Ohno S (eds) Immunology of Behçet’s disease. Swets & Zeitlinger, Lisse, Tokyo, pp 1–16.

    Google Scholar 

Literatur zu Abschnitt 14.4

  • Acar MA, Birch MK, Abbott R et al (1993), Chronic granulomatous anterior uveitis associated with multiple sclerosis, Graefes Arch Clin Exp Ophthalmol, 231(3): p. 166–8.

    Article  PubMed  CAS  Google Scholar 

  • Adamus G, Amundson D, Vainiene M et al (1996), Myelin basic protein specific T-helper cells induce experimental anterior uveitis, J Neurosci Res, 44(6): p. 513–8.

    Article  PubMed  CAS  Google Scholar 

  • Arnold AC, Pepose JS, Hepler RS et al (1984), Retinal periphlebitis and retinitis in multiple sclerosis. I. Pathologic characteristics, Ophthalmology, 91(3): p. 255–62.

    CAS  Google Scholar 

  • Beck RW, Chandler DL, Cole SR et al (2002), Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses, Ann Neurol, 51(4): p. 481–90.

    Article  PubMed  CAS  Google Scholar 

  • Becker M, Davis J (2005), Vitrectomy in the treatment of uveitis, Am J Ophthalmol, 140(6): p. 1096–105.

    Article  PubMed  Google Scholar 

  • Becker MD, Heiligenhaus A, Hudde T et al (2005), Interferon as a treatment for uveitis associated with multiple sclerosis, Br J Ophthalmol, 89(10): p. 1254–7.

    Article  PubMed  CAS  Google Scholar 

  • Becker MD, Wiehler U, Miller DW (2007) Vasculitis in Multiple Sklerosis. In: Joussen AM, Gardner TW, Kirchhof B, Ryan SJ (Hrsg) Retinal Vascular Disease. Springer Berlin Heidelberg, p 650–656

    Google Scholar 

  • Bloch-Michel E, Nussenblatt RB (1987), International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease, Am J Ophthalmol, 103(2): p. 234–5.

    PubMed  CAS  Google Scholar 

  • BregerbcLeopold IH (1966), The incidence of uveitis in multiple sclerosis, Am J Ophthalmol, 62(3): p. 540–5.

    Google Scholar 

  • CHAMPS Study Group (2001), Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis, Am J Ophthalmol, 132(4): p. 463–71.

    Article  Google Scholar 

  • Dhib-Jalbut S (1997), Mechanisms of interferon beta action in multiple sclerosis, Mult Scler, 3(6): p. 397–401.

    Article  PubMed  CAS  Google Scholar 

  • Galetta SL (2001), The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study), J Neuroophthalmol, 21(4): p. 292–5.

    Article  PubMed  CAS  Google Scholar 

  • Jacobs LD, Beck RW, Simon JH et al (2000), Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group, N Engl J Med, 343(13): p. 898–904.

    Article  PubMed  CAS  Google Scholar 

  • Jakob E, Reuland MS, Mackensen F et al (2009), Uveitis subtypes in a german interdisciplinary uveitis center–analysis of 1916 patients, J Rheumatol, 36(1): p. 127–36.

    PubMed  Google Scholar 

  • Jiang H, Milo R, Swoveland P et al (1995), Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells, J Neuroimmunol, 61(1): p. 17–25.

    Article  PubMed  Google Scholar 

  • Mackensen F, Heinz C, Becker MD et al (2008), Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study, Retina, 28(1): p. 41–5.

    Article  PubMed  Google Scholar 

  • Mansour AM, Arevalo JF, Ziemssen F et al (2009), Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization, Am J Ophthalmol, 148(2): p. 310–316 e2.

    Article  PubMed  CAS  Google Scholar 

  • PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998), Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis., Lancet, 352(9139): p. 1498–504.

    Article  Google Scholar 

  • PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS, Neurology, 56(12): p. 1628–36.

    Google Scholar 

  • Rothova A, Buitenhuis HJ, Meenken C et al (1992), Uveitis and systemic disease, Br J Ophthalmol, 76(3): p. 137–41.

    Article  PubMed  CAS  Google Scholar 

  • Satoh J, Paty DWKim SU (1995), Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes, Neurology, 45(2): p. 367–73.

    PubMed  CAS  Google Scholar 

  • Shikishima K, Lee WR, Behan WM et al (1993), Uveitis and retinal vasculitis in acute experimental allergic encephalomyelitis in the Lewis rat: an ultrastructural study, Exp Eye Res, 56(2): p. 167–75.

    Article  PubMed  CAS  Google Scholar 

  • Verhagen C, Mor FCohen IR (1994), T cell immunity to myelin basic protein induces anterior uveitis in Lewis rats, J Neuroimmunol, 53(1): p. 65–71.

    Article  PubMed  CAS  Google Scholar 

  • Villarroya H, Klein C, Thillaye-Goldenberg B et al (2001), Distribution in ocular structures and optic pathways of immunocompetent and glial cells in an experimental allergic encephalomyelitis (EAE) relapsing model, J Neurosci Res, 63(6): p. 525–35.

    Article  PubMed  CAS  Google Scholar 

  • Yong VW, Chabot S, Stuve O et al (1998), Interferon beta in the treatment of multiple sclerosis: mechanisms of action, Neurology, 51(3): p. 682–9.

    PubMed  CAS  Google Scholar 

  • Zierhut MFoster CS (1992), Multiple sclerosis, sarcoidosis and other diseases in patients with pars planitis, Dev Ophthalmol, 23: p. 41–7.

    Google Scholar 

Literatur zu Abschnitt 14.5

  • Asukata Y, Ishihara M, Hasumi Y, Nakamura S, Hayashi K, Ohno S, Mizuki N (2008). Guidelines for the diagnosis of ocular sarcoidosis. Ocul Immunol Inflamm. 16;77–81.

    Article  PubMed  Google Scholar 

  • Baughman RP, Costabel U, du Bois RM (2008) Treatment of sarcoidosis. Clin Chest Med 29: 533–548

    Article  PubMed  Google Scholar 

  • Baughman RP, Drent M, Kavuru M et al.; Sarcoidosis Investigators (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174: 795–802

    Article  PubMed  CAS  Google Scholar 

  • Baughman RP, Lower EE, du Bois RM (2003) Sarcoidosis. Lancet 361: 1111–1118

    Article  PubMed  CAS  Google Scholar 

  • Costabel U (2001) Sarcoidosis: clinical update. Eur Respir J Suppl 32:59s,62s,63s

    Google Scholar 

  • Heiligenhaus A, Wefelmeyer D, Wefelmeyer E, Rösel M, Schrenk M (2011) The eye as a common site for the early clinical manifestation of sarcoidosis. Ophthalmic Res 46:9–12.

    Article  PubMed  Google Scholar 

  • Herbort CP, Rao NA, Mochizuki M; members of Scientific Committee of First International Workshop on Ocular Sarcoidosis (2009). International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOs). Ocul Immunol Inflamm. 17:160–9.

    Article  PubMed  CAS  Google Scholar 

  • Heinz C, Steuhl KP, Heiligenhaus A. (2005) Uveitis in childhood sarcoidosis. Klin Monbl Augenheilkd. 222:348–52.

    Article  PubMed  CAS  Google Scholar 

  • Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357: 2153–2165

    Article  PubMed  CAS  Google Scholar 

  • Lynch JP (2003) Computed tomographic scanning in sarcoidosis. Semin Respir Crit Care Med 24: 393–418

    Article  PubMed  Google Scholar 

  • Ma Y, Gal A, Koss MN (2007) The pathology of pulmonary sarcoidosis: update. Semin Diagn Pathol 24: 150–161

    Article  PubMed  Google Scholar 

  • Muller-Quernheim J, Schurmann M, Hofmann S et al. (2008) Genetics of sarcoidosis. Clin Chest Med 29: 391–414

    Article  PubMed  Google Scholar 

  • Nunes H, Brillet PY, Valeyre D et al. (2007) Imaging in sarcoidosis. Semin Respir Crit Care Med 28: 102–120

    Article  PubMed  Google Scholar 

  • Prasse A, Muller-Quernheim J (2009) Sarkoidose. Internist. 50:581–90.

    Article  PubMed  CAS  Google Scholar 

  • Rosenbaum JT, Rosenzweig HL, Smith JR, Martin TM, Planck SR (2008). Uveitis secondary to bacterial products. Ophthalmic Res. 40:165–8.

    Article  PubMed  Google Scholar 

  • Zissel G, Prasse A, Müller-Quernheim J (2007) Sarcoidosis – immunopathogenetic concepts. J Semin Respir Crit Care Med 28: 3–14

    Article  Google Scholar 

Literatur zu Abschnitt 14.6

  • Balansard B, Bodaghi B, Cassoux N et al (2005) Necrotising retinopathies simulating acute retinal necrosis syndrome. BJOphthalmology 89: 96–101

    CAS  Google Scholar 

  • Bullen CL, Liesegang TJ, McDonald TJ et al (1983) Ocular complications of Wegener’s granulomatosis. Ophthalmology 90: 279–90

    PubMed  CAS  Google Scholar 

  • El-Asrar AMA, Herbort CP, Tabbara KF (2009) Retinal Vasculitis. In: Gupta A, Gupta V, Herbort CP, Khairallah M (Hrsg.) Uveitis-Text and Imaging. Jaypee, New Dehli, S 376–96

    Google Scholar 

  • Field HF (2001) Herpes simplex virus antiviral drug resistance-current trends and future prospects. JClinVirol 21: 261–69

    CAS  Google Scholar 

  • Forster DJ, Dugel PU, Frangieh GT et al (1990) Rapidley progressive outer retinal necrosis in the acquired immunodeficiency syndrome. AmJOphthalmol 110: 341–48

    CAS  Google Scholar 

  • Ganatra JB, Chandler D, Santos BS et al (2000) Viral Causes of the Acute Retinal Necrosis Syndrome. AmJOphthalmol 129: 166–72

    CAS  Google Scholar 

  • Herold G (2002) Vaskulitiden. In: Herold G (Hrsg) Innere Medizin. S 558–564

    Google Scholar 

  • Hillenkamp J, Nolle B, Bruns C et al (2009) Acute Retinal Necrosis: Clinical Features, Early Vitrectomy and Outcomes. Ophthalmolgy 116(10): 1971–5

    Article  Google Scholar 

  • Holland GN, Cornell PJ, Park MS et al (1989) An association between acute retinal necrosis syndrome and HLA-DQw7 and phenotype Bw62, DR4. AmJOphthalmol 108(4): 370–74

    CAS  Google Scholar 

  • Holland GN, Executive Committee of the American Uveitis Society (1994) Standard Diagnostic Criteria for the Acute Retinal Necrosis Syndrome. AmJOphthalmol 117(5): 663–67

    CAS  Google Scholar 

  • Jenette JC, Falk RF, Andrassy K et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37(2): 187–92

    Article  Google Scholar 

  • Manger B, Burmester G (2007) Systemische Autoimmunopathien und Vaskulitiden. In: Gerok W, HÜber Ch, Meinertz Th, Zeidler (Hrsg) Die innere Medizin. Schattauer, Stuttgart, New York, S 1171–85

    Google Scholar 

  • Müller-Hermelink HK (1994) Störungen der Individualitätswahrung, Immunpathologie. In Grundmann E (Hrsg) Einführung in die allgemeine Pathologie. Gustav Fischer, Stuttgart, Jena, New York, S 94–98

    Google Scholar 

  • Pleyer U, Winterhalter S (2010) Diagnostik und Therapie der Herpesvirus-assoziierten Uveitis. Klin Monatsbl Augenheilkd 227:1–6

    Article  Google Scholar 

  • Rothova A, de Boer JH, Ten Dam-van Loon NH et al (2008) Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis. Ophthalmology 115: 306–11

    Article  PubMed  Google Scholar 

  • Scott IU. Luu KM, Davis JL (2000) Intravitreal Antivirals in the Management of Immunocompetent Patients With Necrotizing Herpetic Retinopathy. AmJOphthalmol 129(6): 811–13

    Google Scholar 

  • Urayama A, Yamada N, Sasaki T (1971) Unilateral acute uveitis with periarteritis and retinal detachment. JpnJClinOphthalmol 25: 607–19

    Google Scholar 

  • Winterhalter S, Adams O Althaus C et al (2007) Akute Retinanekrose. Klin Monatsbl Augenheilkd 24: 567–74

    Article  Google Scholar 

Literatur zu Abschnitt 14.7

  • Alexander T, Klotz O, Feist E, Ruther K, Burmester GR, Pleyer U (2005) Successfull treatment of acute visual loss in Muckle- Wells syndrome with interleukin 1 receptor antagonist. Ann Rheum Dis 64: 1245–6

    Article  PubMed  CAS  Google Scholar 

  • Bhat P, Castaneda-Cervantes RA, Foster CS (2009) Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol 247(5): 687–92

    Article  PubMed  CAS  Google Scholar 

  • Deuter CM (2010) Systemic voclosporin for uveitis treatment. Ophthalmologe 107(7): 672–5

    Article  PubMed  CAS  Google Scholar 

  • Feldmann W (2000) Evidence-based Pediatrics. 1ed.Hamilton: B.Decker

    Google Scholar 

  • Heiligenhaus A, Mingels A, Heinz C et al (2007) Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional antiinflammatory medication. Eur J Ophthalmol 17: 743–748

    PubMed  CAS  Google Scholar 

  • Heiligenhaus A, Horneff G, Greiner K et al (2007) Inhibitors of Tumor Necrosis Factor-alpha for the Treatment of Arthritis and Uveitis in Childhood. Klin Monatsbl Augenheilkd 224: 526–531

    Article  PubMed  CAS  Google Scholar 

  • Imrie FR, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmology 18: 481–86

    Article  Google Scholar 

  • Jabs DA, Rosenbaum JT, Foster CS et al (2000) Perspective: Guidelines for the Use of Immunosuppressive Drugs in Patients With Ocular Inflammatory Disorders: Recommendations of an Expert Panel. Am J Ophthalmol 130(4): 492–513

    Article  PubMed  CAS  Google Scholar 

  • Kakkassery V, Mergler S, Pleyer U (2010) Anti- TNF- alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 35(8): 751–6

    Article  PubMed  CAS  Google Scholar 

  • Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades- Behçet’s disease treated with interferon- alpha- 2a. J Rheumatol 35 (5): 896–903

    PubMed  CAS  Google Scholar 

  • Ness T, Paulus W (2010) Eye and pregnancy. Der Ophthalmologe 107(9):863–72

    Article  PubMed  CAS  Google Scholar 

  • Nussenblatt RB, Peterson JS, Foster CS et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5): 764–70

    Article  PubMed  Google Scholar 

  • Rudwaleit R, Rǿdevand E, Holck P et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis &8(5): 696–701

    Article  CAS  Google Scholar 

  • Sen HN, Levy-Clarke G, Faia LJ et al (2009) High-dose Daclizumab for the Treatment of Juvenile Idiopathic Arthritis- Associated Active Anterior Uveitis. Am J Ophthalmol 148(5): 696–703

    Article  PubMed  CAS  Google Scholar 

  • Sharma SM, Nestel AR, Lee RWJ et al (2009) Clinical Review: Anti-TNFα Therapies in Uveitis: Perspective on 5 Years of Clinical Experience. Ocular Immunology and Inflammation 17(6): 403–414

    Article  PubMed  CAS  Google Scholar 

  • Smith JA, Thompson DJ, Whitcup SM et al (2005) A randomized, placebo controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53: 18–23

    Article  PubMed  CAS  Google Scholar 

  • Tappeiner C, Roesel M, Heinz C et al (2009) Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye 23(5):1192–8.

    Article  PubMed  CAS  Google Scholar 

  • Taylor SR, Salama AD, Joshi L et al (2009) Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum 60(5): 1540–7

    Article  PubMed  Google Scholar 

  • Tynjala P, Lindahl P, Honkanen V et al (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66: 548–50

    Article  PubMed  CAS  Google Scholar 

  • Winterhalter S, Niehues T (2008) TNF alpha- blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? – an evidence based approach. Klin Padiatr 220(6): 342–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Augenheilkunde, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin

    Univ.-Prof. Dr. med. Antonia M. Joussen

Authors
  1. Univ.-Prof. Dr. med. Antonia M. Joussen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Joussen, A.M. (2012). Entzündliche Gefäßerkrankungen. In: Retinale Gefäßerkrankungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18021-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18021-7_14

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-18020-0

  • Online ISBN: 978-3-642-18021-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation